Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines approved by the European Medicines Agency and the US Food and Drug Administration that have been scored and published by ESMO.

ESMO-MCBS scores are based on peer reviewed clinical trial reports. They are generated using a validated standard methodology and are reviewed by a team of clinicians and statisticians before publication. ESMO-MCBS scores should be interpreted in the context of an evolving treatment landscape, in connection with clinical practice guidelines.

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 22
4 135
3 156
2 55
1 24
NEB 4
Curative setting
A 54
C 3
NEB 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 4
Breast Cancer 39
Endocrine Tumours 21
Gastrointestinal Cancers 76
Genitourinary Cancers 70
Gynaecological Malignancies 38
Head and neck cancer 12
Non-cancerous soft-tissue tumour 1
Sarcoma 13
Skin Cancers 29
Thoracic Malignancies 86
TMB-H solid tumours 1
Tumour agnostic 6
Curative setting
Brain Tumours 2
Breast Cancer 9
Endocrine Tumours 0
Gastrointestinal Cancers 16
Genitourinary Cancers 3
Gynaecological Malignancies 1
Head and neck cancer 1
Non-cancerous soft-tissue tumour 0
Sarcoma 3
Skin Cancers 14
Thoracic Malignancies 11
TMB-H solid tumours 0
Tumour agnostic 0

The ESMO-MCBS Scorecards

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Therapeutic Indication Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole) - Surgery alone (Pooled-analysis) Patients with stage II and III colon cancer
    Gastrointestinal Cancers
    		 Colon Cancer - -

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F1

      A
    5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole) - Surgery alone (Meta-analysis) Patients with resected stage II and III colon cancer
    Gastrointestinal Cancers
    		 Colon Cancer - -

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F1

      A
    5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole) - Surgery alone (Meta-analysis) Patients with resected stage II and III colon cancer
    Gastrointestinal Cancers
    		 Colon Cancer - -

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F1

      A
    5FU/LEV (5-fluorouracil + levamisole) - Levamisole Resected stage III (Dukes stage C) colon cancer Intergroup 0035
    Gastrointestinal Cancers
    		 Colon Cancer - Intergroup 0035

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Tivozanib - Sorafenib Adult patients with relapsed or refractory advanced RCC following ≥2 prior systemic therapies TIVO-3
    Genitourinary Cancers
    		 Renal cell cancer - TIVO-3

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Enzalutamide ADT (androgen deprivation therapy) Placebo + ADT For the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy ARCHES
    Genitourinary Cancers
    		 Prostate cancer - ARCHES

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Lorlatinib - Crizotinib Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive (NSCLC) previously not treated with an ALK inhibitor CROWN
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ALK+ CROWN

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Sacituzumab govitecan - Physician’s choice of single agent ChT Treatment of patients with unresectable or metastatic TNBC who have received ≥2 prior systemic therapies, ≥1 of them for advanced disease ASCENT
    Breast Cancer
    		 Breast Cancer Triple-negative ASCENT

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Nivolumab Cabozantinib Sunitinib First-line treatment of adult patients with advanced RCC CheckMate-9ER
    Genitourinary Cancers
    		 Renal cell cancer - CheckMate-9ER

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Atezolizumab - Single arm (Phase II) Single-arm study of atezolizumab in patients with locally advanced or metastatic urothelial bladder cancer IMvigor210 (Cohort 2)
    Genitourinary Cancers
    		 Urothelial Carcinoma - IMvigor210 (Cohort 2)

    1

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      1
    Enfortumab vedotin - Single arm (Phase II) Patients with locally advanced or metastatic UC who are ineligible for cisplatin-containing ChT and have previously received ≥1 prior lines of therapy EV-201 - Cohort 2
    Genitourinary Cancers
    		 Urothelial Carcinoma - EV-201 - Cohort 2

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Erdafitinib - Single arm (Phase II) Locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations and disease progression during/after ≥1 prior platinum-containing ChT BLC2001
    Genitourinary Cancers
    		 Urothelial Carcinoma FGFR3 or FGFR2 genetic alterations BLC2001

    1

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      1
    Pembrolizumab - Single arm Locally advanced or metastatic UC in adults who are not eligible for cisplatin-containing ChT and whose tumours express PD-L1 with a CPS ≥10 KEYNOTE-052
    Genitourinary Cancers
    		 Urothelial Carcinoma PD-L1 CPS ≥10% KEYNOTE-052

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Pembrolizumab - Investigator’s choice of ChT (paclitaxel, docetaxel or vinflunine) Locally advanced or metastatic UC in adults who have received prior platinum-containing ChT KEYNOTE-045
    Genitourinary Cancers
    		 Urothelial Carcinoma - KEYNOTE-045

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Nivolumab - Placebo Adjuvant therapy for adult patients with oesophageal or gastroesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy CheckMate 577
    Gastrointestinal Cancers
    		 Oesophageal or gastroesophageal junction carcinoma - CheckMate 577

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Sotorasib - Single arm Treatment of adults with advanced non-small cell lung cancer with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy CodeBreaK 100
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer KRAS G12C mutated CodeBreaK 100

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Cemiplimab - Single arm (Phase II) Treatment of basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI) Study 1620
    Skin Cancers
    		 Basal Cell Carcinoma - Study 1620

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Nivolumab + ipilimumab - Single arm FDA: Treatment of adult patients with dMMR or MSI-H mCRC after prior fluoropyrimidine-based combination ChT. EMA: Nivolumab in combination with ipilimumab for the treatment adult patients with dMMR or MSI-H colorectal cancer after prior fluoropyrimidine based combination chemotherapy CheckMate142
    Gastrointestinal Cancers
    		 Colorectal Cancer dMMR+ or MSI-H+ CheckMate142

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Pemetrexed Cisplatin Cisplatin In combination with cisplatin for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma EMPHACIS
    Thoracic Malignancies
    		 Pleural mesothelioma - EMPHACIS

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Lenvatinib Pembrolizumab Sunitinib Treatment of adults with advanced renal cell carcinoma in combination with pembrolizumab as first-line treatment CLEAR
    Genitourinary Cancers
    		 Renal cell cancer - CLEAR

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Pembrolizumab ChT (paclitaxel + carboplatin) Placebo plus ChT (paclitaxel + carboplatin) In combination with ChT as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early‑stage triple‑negative breast cancer at high risk of recurrence KEYNOTE-522
    Breast Cancer
    		 Early Breast Cancer Triple-negative KEYNOTE-522

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Enfortumab vedotin - Investigator-chosen ChT (standard docetaxel, paclitaxel or vinflunine) Treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor EV-301
    Genitourinary Cancers
    		 Urothelial Carcinoma - EV-301

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Pembrolizumab - Single arm Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy KEYNOTE-057
    Genitourinary Cancers
    		 Urothelial Carcinoma - KEYNOTE-057

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Nivolumab Fluoropyrimidine + platinum ChT (FOLFOX or CAPOX) ChT (FOLFOX or CAPOX) Treatment for adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and oesophageal adenocarcinoma CheckMate 649
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction cancer and oesophageal adenocarcinoma - CheckMate 649

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Nivolumab Fluoropyrimidine + platinum ChT (FOLFOX or CAPOX) ChT (FOLFOX or CAPOX) First‑line treatment for patients with HER2‑negative advanced or metastatic gastric, gastroesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a CPS ≥5 CheckMate 649
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction cancer and oesophageal adenocarcinoma HER2- PD-L1 CPS ≥5 CheckMate 649

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Pralsetinib - Single arm Treatment for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test ARROW
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer RET fusion-positive ARROW

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Pralsetinib - Single arm Treatment for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor ARROW
    Breast Cancer
    		 Non-small-cell Lung Cancer RET fusion-positive ARROW

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Pembrolizumab - Single arm cohort study Patients with unresectable or metastatic dMMR/MSI-H solid tumours that have progressed following prior treatment and have no alternative treatment options KEYNOTE-158 - Cohort K
    Tumour agnostic
    		 - dMMR/MSI-H KEYNOTE-158 - Cohort K

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Trastuzumab ChT (cisplatin + capecitabine or 5-FU) ChT HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction in patients who have not received prior anti-cancer treatment for their metastatic disease ToGA
    Gastrointestinal Cancers
    		 Stomach or gastroesophageal junction cancer HER2+ ToGA

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Ivosidenib - Placebo For adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy. ClarIDHy
    Gastrointestinal Cancers
    		 Cholangiocarcinoma IDH1 ClarIDHy

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.